Showing 1041-1050 of 19239 results for "".
RAS(ON) and Beyond: Clinical Integration and Strategic Sequencing
https://reachmd.com/programs/cme/rason-and-beyond-clinical-integration-and-strategic-sequencing/54124/Explore ON-state RAS inhibitors for the treatment of NSCLC and pancreatic cancer, including mechanisms, efficacy data, and integration into clinical practice.Optimizing Hyperkalemia Management: Clinical Implications and Risk Assessment
https://reachmd.com/programs/cme/tbd/37670/Learn from a multidisciplinary faculty panel how to Improve outcomes for patients with CKD and HFrEF using optimal RAASi and MRAs while managing hyperkalemia with potassium binders.Test Your Skills and Learn From Experts on IL-13 Inhibitors in Moderate to Severe Atopic Dermatitis
https://reachmd.com/programs/cme/test-your-skills-and-learn-from-experts-on-il-13-inhibitors-in-moderate-to-severe-atopic-dermatitis/37624/Watch an expert-led case discussion on the role of IL-13 in moderate to severe atopic dermatitis and the efficacy on its inhibition through biologic therapies to achieve control.The Road to Denver – Targeting IL-31: A Case-Based Journey
https://practicaldermatology.com/series/nemluvio-peer-network/the-road-to-denver-targeting-il-31-a-case-based-journey/56419/Join Dr Raj Chovatiya, Dr Mona Shahriari, and Dr Jonathan Silverberg as they discuss Targeting the IL-31 Neuroimmune Pathway: A Case-Based Approach. This Product Theater will take place Sunday, March 29, 2026, from 10:30–11:15 AM MT at the Colorado Convention Center, Theater 1 in Denver, Colorado. PPrecision Starts Before Birth: Reimagining Fetal Care Through FcRn Immune Modulation
https://reachmd.com/programs/cme/Precision-Starts-Before-Birth-Reimagining-Fetal-Care-Through-FcRn-Immune-Modulation/37099/Explore FcRn inhibition as a preventive strategy for HDFN and FNAIT, with focus on ongoing trials including AZALEA and FREESIA.Chairperson's Perspective: Innovative Approaches to IBS-C: Personalized Treatment for Better Outcomes
https://reachmd.com/programs/cme/chairpersons-perspective-innovative-approaches-to-ibs-c-personalized-treatment-for-better-outcomes/27169/Join us to discover the impact of IBS-C on patients’ QoL and find out how to apply advances in its treatment & management.Case Application: Frontline Insights—Tackling Newly Diagnosed Myeloma
https://reachmd.com/programs/cme/case-application-frontline-insightstackling-newly-diagnosed-myeloma/36573/Beyond the Horizon in Multiple Myeloma: Harnessing Novel CELMoD Mechanisms for Increased Antimyeloma ActivityDiagnosing IBS-C: From Clinical Clues to Confident Calls
https://reachmd.com/programs/clinicians-roundtable/diagnosing-ibs-c-from-clinical-clues-to-confident-calls/29891/Among patients with irritable bowel syndrome with constipation (IBS-C), only 24 percent have a diagnosis, while 62 percent remain undiagnosed and seeking care.1 And when IBS goes undiagnosed, patients can experience prolonged pain, suffering, and anxiety due to the disease and its associated comorbiUnderstanding the Mechanism Behind a Treatment Approach in Indolent Systemic Mastocytosis (ISM)
https://reachmd.com/programs/medical-industry-feature/mechanism-treatment-approach-indolent-systemic-mastocytosis-ism/32766/Historically, indolent systemic mastocytosis (ISM) care focused on treating symptoms. AYVAKIT® (avapritinib) targets the KIT D816V mutation, the underlying cause of ISM.3,4 Learn how AYVAKIT can play a role in treating patients with ISM.1Implementing the Latest Diagnostic and Treatment Approaches for Generalized Myasthenia Gravis
https://reachmd.com/programs/cme/implementing-the-latest-diagnostic-and-treatment-approaches-for-generalized-myasthenia-gravis/32961/Examine FcRn inhibitors in gMG with expert discussion on mechanisms, clinical trial results, therapeutic use, and individualized treatment approaches.